AlphAIAlphAI — Financial news for AI agents
StockOTC · US · USDHealthcare · Biotechnology

$OTLC

Oncotelic Therapeutics, Inc.

Price · $OTLCvia TradingView
AI sentiment · 7d1 articles
OCT 7net (bullish − bearish)OCT 13
Bullish
0
Neutral
1
Bearish
0
Insider · 30dAll trades →

No SEC Form 4 filings for $OTLC in the last 30 days.

See all $OTLC insider activity →
Top stories · $OTLCMore →
OCT 13·tradingview.comLow

Oncotelic Therapeutics presents PDAOAI platform and HCC four-gene signature at Drug Discovery 2026

Oncotelic Therapeutics presented its PDAOAI platform and a four-gene mTOR-related signature linked to HCC survival at Drug Discovery 2026. The platform includes a search and evidence-aggregation workflow with ~29 million PubMed abstracts. The company cautioned that findings are retrospective and do not predict therapy benefits. Oncotelic also invited proposals for its BIO REBOOT initiative, offering potential funding and support.

AUG 4·SEC EDGAR 8-K

Oncotelic Therapeutics, Inc. (OTLC): Entry into a Material Definitive Agreement

Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 3, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2026 Pacific Pier SPA 2 ”), with Pacific Pier Capital II, LP (“ Pacific Pier ”), and the Company issue

JUL 14·SEC EDGAR 8-K

Oncotelic Therapeutics, Inc. (OTLC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (this “ Agreement ”) is made and entered into as of July 10, 2026 (the “ Grant Date ”) by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “ Company

OTLC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning OTLC (Oncotelic Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent OTLC coverage spans insider activity, corporate actions and technology.

What's driving OTLC

  • The platform introduction is a early‑stage research tool with limited immediate market impact.

    tradingview.com · Oct 13, 2026

  • The filing discloses a new convertible debt and equity issuance arrangement, which can pressure dilution expectations and change near-term financing risk.

    SEC EDGAR 8-K · Aug 4, 2026

  • The filing signals management compensation is contingent on achieving a national exchange uplisting, which can affect perceived execution risk and governance optics.

    SEC EDGAR 8-K · Jul 14, 2026

  • Insider open-market purchase by the CEO/Chairman can be read as confidence, but it is not a fundamental catalyst like guidance, trial data, or financing.

    SEC EDGAR · Jul 2, 2026

  • The filing discloses a new convertible debt/equity-linked financing that can dilute common holders upon conversion and may pressure near-term sentiment.

    SEC EDGAR 8-K · Jun 29, 2026

AlphAI scores every news story that mentions OTLC with an AI model for sentiment and relevance, and aggregates insider trades from Oncotelic Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $OTLC

Score
OCT 13$OTLCLowtradingview.com

Oncotelic Therapeutics presents PDAOAI platform and HCC four-gene signature at Drug Discovery 2026

Oncotelic Therapeutics presented its PDAOAI platform and a four-gene mTOR-related signature linked to HCC survival at Drug Discovery 2026. The platform includes a search and evidence-aggregation workflow with ~29 million PubMed abstracts. The company cautioned that findings are retrospective and do not predict therapy benefits. Oncotelic also invited proposals for its BIO REBOOT initiative, offering potential funding and support.

1 min read
AUG 4$OTLCMedSEC EDGAR 8-K

Oncotelic Therapeutics, Inc. (OTLC): Entry into a Material Definitive Agreement

Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 3, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2026 Pacific Pier SPA 2 ”), with Pacific Pier Capital II, LP (“ Pacific Pier ”), and the Company issue

4 min read
JUL 14$OTLCLowSEC EDGAR 8-K

Oncotelic Therapeutics, Inc. (OTLC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (this “ Agreement ”) is made and entered into as of July 10, 2026 (the “ Grant Date ”) by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “ Company

3 min read
JUN 29$OTLCMedSEC EDGAR 8-K

Oncotelic Therapeutics, Inc. (OTLC): Entry into a Material Definitive Agreement

Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 23, 2026, by and between ONCOTELIC THERAPEUTICS, INC. , a Delaware corporation, with headquarters located at 29397 Agoura Road Suite 107,

4 min read

Related tickers

More in Biotechnology